What compounded semaglutide actually is
Semaglutide is the active ingredient in brand medications like Wegovy (weight loss) and Ozempic (diabetes). Brand-name semaglutide is manufactured by Novo Nordisk under strict FDA oversight, tested for purity, and approved for specific uses.
Compounded semaglutide is made by specialized pharmacies using pharmaceutical ingredients they combine themselves. It is not manufactured by Novo Nordisk and is not FDA-approved in the same way brand medications are.
Two types of compounding pharmacy
- 503B pharmacies (outsourcing facilities): larger, registered with the FDA, and able to compound without a patient-specific prescription. Some compound semaglutide at scale.
- 503A pharmacies (traditional): smaller local pharmacies that compound only against a valid individual prescription.
Both operate under less oversight than FDA-approved manufacturers. The FDA historically allows compounding during documented shortages — which is why the February 2025 shortage ending matters so much.
Side-by-side: the key differences
| Factor | Brand-name (Wegovy) | Compounded |
|---|---|---|
| FDA approval | FDA-approved; clinically tested | Not FDA-approved; different oversight |
| Made by | Novo Nordisk (pharmaceutical company) | Local or regional compounding pharmacy |
| Quality testing | Rigorous batch testing for purity, potency, sterility | Varies by pharmacy; no standardized requirement |
| Dosing accuracy | Pre-filled pens with exact, verified doses | May vary slightly between batches |
| Clinical evidence | Extensive trials proving safety and efficacy | No clinical trials on compounded versions |
| Monthly cost | $1,000–1,300 cash; $250–500 with insurance | $100–400 plus telehealth fees ($150–300) |
The FDA shortage ruling explained
In February 2025, the FDA officially declared that the semaglutide shortage had ended. This matters because the FDA permits compounding of brand-name drugs primarily during documented shortages.
With the shortage officially over, the FDA's legal justification for allowing semaglutide compounding no longer applies. In practice that means:
- Compounding pharmacies' legal ability to compound semaglutide is now questionable
- The FDA could take enforcement action against compounders continuing without a documented shortage
- Some pharmacies may discontinue semaglutide compounding entirely
- Availability may decrease significantly over the next 6–12 months
The FDA has not issued a blanket prohibition, but the legal landscape has shifted. If you are relying on compounded semaglutide, plan for the possibility that your pharmacy stops supplying it.
The six safety concerns
These are the specific, documented gaps between a compounded product and an FDA-approved one. Not every one will apply to every pharmacy, but each is a real reason the two are not interchangeable.
Contamination risk
Compounding pharmacies prepare medications in-house, which introduces contamination risks absent from pharmaceutical manufacturing. The FDA has documented quality problems with compounded GLP-1 products, including bacterial contamination, non-sterile ingredients, and foreign particles. Such incidents are relatively rare, but they can harm patients.
Dosing accuracy varies
Brand Wegovy comes in pre-filled pens with exact, verified doses. Compounded semaglutide may vary between batches. A dose meant to be 0.5 mg might actually be 0.47 mg or 0.53 mg — small differences that affect efficacy and safety over time.
No clinical trials on compounded versions
All safety and efficacy data for semaglutide comes from trials of brand-name Wegovy and Ozempic. There are no clinical trials of compounded semaglutide. The active ingredient is the same, but the lack of evidence on the finished compounded product is a genuine gap.
Reported adverse events
The FDA has received reports of adverse events from compounded semaglutide products, including dosing errors that led to gastrointestinal effects, dehydration, acute pancreatitis, and hospitalizations. Causation is hard to establish for any single report, but the pattern suggests compounded products may not be equivalent to brand versions.
Limited safety monitoring
Brand manufacturers are required to monitor and report adverse events. Compounding pharmacies have no equivalent systematic requirement, so safety issues with compounded semaglutide may go unreported and untracked.
Ingredient sourcing questions
Compounding pharmacies source semaglutide from pharmaceutical suppliers, but the supply chain for compounding ingredients is less transparent than for FDA-approved drugs. The origin of a given batch is often unclear.
What each option really costs
The headline saving on compounded semaglutide is real, but it shrinks once you count the telehealth fees that almost always come with it. Compare the total, not the pharmacy price.
Three-month total cost
| Option | Pharmacy cost | Telehealth cost | Total |
|---|---|---|---|
| Brand Wegovy (cash) | $3,000–3,900 | $0 (included) | $3,000–3,900 |
| Brand Wegovy (insurance) | $750–1,500 | $0 | $750–1,500 |
| Compounded | $300–1,200 | $450–900 | $750–2,100 |
Worth noticing: brand-name Wegovy with insurance and compounded semaglutide with telehealth fees can land at the same three-month total. If you have any coverage at all, price the brand option before assuming compounded is cheaper.
Whichever route you take, the single biggest safety factor is having a clinician actively monitoring your dose and response. Telehealth programs that include ongoing clinical oversight in the price are where that happens.
Compare what you would actually pay
Found covers both brand-name and compounded options with insurance support and ongoing clinician oversight. Our link carries partner pricing: $100 off your first month, plus $50 off compounded GLP-1s with code SAVE50.
Check Found pricing →How to choose
Choose brand-name Wegovy if
- You have insurance coverage, even with a high copay
- You qualify for a patient assistance program
- Safety and clinical evidence are your top priority
- You want the most predictable, consistent dosing
Consider compounded only if
- Cost is a genuine barrier and you have exhausted other options
- You are using a verified, accredited pharmacy
- A provider is actively monitoring your response and safety
- You understand and accept the safety risks
- You are prepared for it to become unavailable
Try these alternatives first
- Wegovy cost reduction strategies — patient assistance, GoodRx, and state programs
- Telehealth programs that work with your insurance
- Our full ranked comparison of GLP-1 programs
- Tirzepatide, which is newer and sometimes cheaper than semaglutide
Common questions
Is compounded semaglutide FDA-approved?
No. The FDA approves brand-name medications like Wegovy, made by pharmaceutical companies under strict oversight. Compounded medications made by pharmacies fall under a different regulatory category. The FDA permits compounding under certain conditions such as shortages, but the products themselves are not FDA-approved.
Is compounded semaglutide safe?
It carries real safety risks. Quality varies by pharmacy, there are no clinical trials, and contamination cases have been reported. It is less safe than brand alternatives, though many patients use it without serious adverse events. Safety depends heavily on the pharmacy's standards and your provider's oversight.
How much can I actually save?
Compounded semaglutide typically costs $100–400/month against $1,000–1,300/month for brand Wegovy, a 70–90% reduction at the pharmacy. Add telehealth fees of $150–300/month and the saving narrows to roughly 30–60% compared with brand plus telehealth. Compare total cost, not pharmacy cost.
What does the February 2025 FDA shortage ruling mean for me?
The shortage ending removes the FDA's legal justification for allowing semaglutide compounding. Over the next 6–12 months, availability may decrease as the FDA clarifies enforcement and pharmacies reassess. If you are considering compounded options, be prepared for potential unavailability.
Can I verify a compounding pharmacy's quality?
Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation, contact your state pharmacy board, and ask about testing protocols for sterility, potency, and purity. Accreditation does not guarantee safety for semaglutide specifically, so request a certificate of analysis for your specific dose.
Which telehealth programs offer compounded vs brand semaglutide?
Hims has historically offered compounded semaglutide at lower cost and is transitioning as brand availability improves. Ro, Calibrate, and Found primarily offer brand-name medications. Offerings change frequently, so always ask a provider directly before enrolling.
The bottom line
Compounded semaglutide is meaningfully cheaper than brand Wegovy and it is not a scam — but it is not the same product, and the gap is widest exactly where it matters most: evidence, consistency, and oversight. If you have any insurance coverage, price the brand option properly before assuming you cannot afford it. If you do go compounded, the pharmacy's credentials and your provider's attention are what carry the safety load.
This article is for educational purposes and does not constitute medical advice. The decision to use compounded semaglutide should be made with a licensed healthcare provider who understands your medical history and risk factors. The FDA and healthcare providers continue to evaluate compounded semaglutide safety and legality. Information reflects the regulatory landscape as of August 2026 and may change. Always verify current information with your provider and pharmacy before making treatment decisions.